A Happy Pill for Some Biotechs
A Happy Pill for Some Biotechs
Analysts predict 2003′s rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers.
A Happy Pill for Some Biotechs
Analysts predict 2003′s rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers.
Biotech: A Coming Boom — or Bust?
Two industry veterans lay out contrasting views about what the sector and its investors can expect over the next 12 months.
Biotech may be poised for “big year”
Biotechnology is poised for a boom year in 2004, wrapping up 2003 with a strong recovery and plenty of reason for optimism, in the forecast of G. Steven Burrill, chief executive officer of the San Francisco-based life sciences merchant bank, Burrill & Co.
When Patents Persist
What if that patent you’re paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible?
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Recent Comments